A costly tool used on nearly all mammograms does not increase cancer detection rates and should no longer be covered by Medicare, argues Joshua Fenton, a family physician and comparative effectiveness researcher.
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now